Open AccessPatients with chronic liver disease and COVID-19 (literature review and own data)
Author(s) -
D.H. Yuldasheva,
Z.X. Muxamedova,
N.S Shadjanova
Publication year - 2021
Publication title -
society and innovations
Language(s) - English
Resource type - Journals
ISSN - 2181-1415
DOI - 10.47689/2181-1415-vol2-iss2/s-pp498-503
Subject(s) - exacerbation , covid-19 , medicine , pandemic , disease , coronavirus , liver disease , liver dysfunction , albumin , chronic liver disease , intensive care medicine , virology , infectious disease (medical specialty) , cirrhosis , outbreak
The pandemic of the new coronavirus COVID-19 has switched medicine around the world on the primary fight against this infection. Patients with chronic liver diseases require increased attention of doctors during an epidemic, since against the background of an exacerbation of their disease, not only the risk of contracting the COVID 19 viral infection increases, but also its more severe course. Patients with confirmed COVID-19 with severe liver damage - high biochemical activity. According to some reports, patients with a severe course of COVID-19 have an increase in ALT levels, a decrease in the number of platelets, a decrease in the level of albumin, and a connection (although not all indicators) with a higher risk of mortality is possible.